In people with uncontrolled type 2 diabetes on an SGLT2 inhibitor, insulin degludec/liraglutide (IDegLira) lowered HbA1c by 21 mmol/mol (1.9%-points) and insulin glargine U100 by 18 mmol/mol (1.7%-points) at week 26.
In plain wordsIn people with uncontrolled type 2 diabetes on an SGLT2 inhibitor, both the IDegLira combination and insulin glargine lowered HbA1c.
- Peptide
- Liraglutide
- Outcome
- DecreaseHbA1c change from baseline to week 26
- Study
n = 420
- Comparator
- Insulin glargine U100 (IGlar U100)
- Analysis
- Primary
- Outcome group
- Glycemic control · Metabolic and weight
Measurements
- HbA1c change
- −21 mmol/mol
- IDegLira
- HbA1c change
- −18 mmol/mol
- IGlar U100
- HbA1c change
- −1.9 %-points
- IDegLira
- HbA1c change
- −1.7 %-points
- IGlar U100
Source sentences
The primary endpoint was change in HbA1c from baseline to week 26.
2 context sentences(design, population, supporting numbers)
Mean HbA1c reductions were 21 mmol/mol (1.9%-points) with IDegLira and 18 mmol/mol (1.7%-points) with IGlar U100;
To investigate the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine 100 units/mL (IGlar U100) as add-on to sodium-glucose co-transporter-2 (SGLT2) inhibitor therapy.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.